Pyxis Oncology to Participate in Two Major Investor Conferences
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing innovative therapies for challenging cancers, has announced its participation in two significant investor conferences. The company's President and CEO, Dr. Lara S. Sullivan, will represent Pyxis, underscoring their dedication to advancing cancer treatment through innovation.
Upcoming Conference Details
The first event is the Morgan Stanley 22nd Annual Global Healthcare Conference, taking place on September 6. Dr. Sullivan will participate in a fireside chat at 12:20 PM Eastern Time, providing investors with insights into the company's strategic direction and ongoing therapeutic developments.
Global Healthcare Conference Insights
This conference is an important venue where healthcare companies share updates on their latest innovations and operational achievements. Additionally, members of Pyxis Oncology’s management team will hold one-on-one meetings with investors, facilitating more in-depth discussions about the company’s vision and research initiatives.
Participation in H.C. Wainwright Conference
The second event is the H.C. Wainwright 26th Annual Global Investment Conference, where Pyxis Oncology will present on September 9 at 2:00 PM Eastern Time. This well-regarded forum attracts numerous public and private companies, allowing them to connect with the investment community and highlighting Pyxis Oncology's proactive efforts in investor relations.
Innovations and Strategies in Therapeutics
These conferences not only provide Pyxis Oncology with a platform to showcase its advancements but also to discuss its ongoing Phase 1 clinical studies involving key therapeutic candidates. The company is making progress with its antibody-drug conjugates (ADCs), including PYX-201, which targets EDB+FN in the tumor stroma, and PYX-106, aimed at enhancing T-cell activity.
Importance of Webcasting
For those unable to attend in person, a live webcast of the presentations will be available, along with a replay option on the Events & Presentations page in the Investor Relations section of Pyxis Oncology's official website. This ensures that the information shared is accessible to a wide audience, promoting transparency and engagement with both current and potential investors.
About Pyxis Oncology, Inc.
Pyxis Oncology is a clinical-stage company dedicated to developing novel therapeutics aimed at combating difficult-to-treat cancers. Their innovative approach includes both monotherapy and combination therapy strategies, supported by a drug pipeline specifically designed to target tumor cells. The therapeutic portfolio also addresses the mechanisms that allow cancer to evade immune responses, offering a comprehensive approach to cancer treatment.
Promising Therapeutic Candidates
Among its promising candidates, PYX-201 is being evaluated for its potential against various solid tumors, while PYX-106 is designed to enhance T-cell functions. Together, these initiatives reflect the company’s commitment to utilizing cutting-edge research to develop impactful cancer therapies that can overcome existing treatment limitations.
Community Engagement Efforts
Pyxis Oncology not only aims for excellence in its scientific pursuits but also values community engagement. The company encourages stakeholders to stay connected and informed through its social media platforms, which are regularly updated with the latest news and developments.
Contact Information for Inquiries
For more information, interested individuals can contact the company's CFO and COO, Pamela Connealy, via email.
Email: ir@pyxisoncology.com
Frequently Asked Questions
What is Pyxis Oncology, Inc.?
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for challenging cancers.
Who will represent Pyxis Oncology at the conferences?
Dr. Lara S. Sullivan, the President and CEO, will represent the company and engage in discussions during the conferences.
When is the Morgan Stanley conference?
The Morgan Stanley 22nd Annual Global Healthcare Conference is scheduled for September 6, starting at 12:20 PM Eastern Time.
What are the key therapeutic candidates of Pyxis Oncology?
Key therapeutic candidates include PYX-201, an antibody-drug conjugate targeting tumor stroma, and PYX-106, designed to enhance T-cell function.
How can I access the conference presentations?
A live webcast and replay of the presentations can be accessed on the Events & Presentations page on Pyxis Oncology's Investor Relations website.